PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 (PMVP) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2020 to Q4 2025

Type / Class
Equity / Common stock, par value $0.00001
Symbol
PMVP on Nasdaq
Shares outstanding
53,185,766
Price per share
$1.25
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
37,328,298
Total reported value
$46,659,218
% of total 13F portfolios
0%
Share change
-94,349
Value change
-$174,773
Number of holders
60
Price from insider filings
$1.25
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 (PMVP) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BML Investment Partners, L.P. 9.9% +60% $6,615,000 +$2,527,616 5,292,000 +62% BML Investment Partners, L.P. 31 Dec 2025
ORBIMED ADVISORS LLC 9.4% $6,965,407 4,975,291 ORBIMED ADVISORS LLC 23 Oct 2025
TANG CAPITAL MANAGEMENT LLC 8.9% $6,702,907 4,720,357 TANG CAPITAL MANAGEMENT, LLC 16 Sep 2025
ArrowMark Colorado Holdings LLC 5.8% $3,862,616 3,090,093 ArrowMark Colorado Holdings, LLC 31 Dec 2025
Sio Capital Management, LLC 5% -32% $3,691,167 -$1,538,387 2,636,548 -29% Sio Capital Management, LLC 30 Sep 2025

As of 31 Dec 2025, 60 institutional investors reported holding 37,328,298 shares of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 (PMVP). This represents 70% of the company’s total 53,185,766 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 (PMVP) together control 68% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BML Capital Management, LLC 10% 5,292,000 0% 5.9% $6,615,000
ORBIMED ADVISORS LLC 9.4% 4,975,291 -17% 0.13% $6,219,114
TANG CAPITAL MANAGEMENT LLC 9.3% 4,940,000 +3.2% 0.31% $6,175,000
ArrowMark Colorado Holdings LLC 5.8% 3,090,093 -6.4% 0.08% $3,862,616
Sio Capital Management, LLC 5% 2,636,548 0% 0.55% $3,295,685
Euclidean Capital LLC 4.9% 2,627,643 0% 0.89% $3,284,554
VANGUARD GROUP INC 4.1% 2,170,310 +0.34% 0% $2,712,888
ACADIAN ASSET MANAGEMENT LLC 3.8% 2,015,770 -2.4% 0% $2,518,000
Stonepine Capital Management, LLC 2.2% 1,150,759 -16% 1.1% $1,438,449
BlackRock, Inc. 2.1% 1,094,883 -0.84% 0% $1,368,605
TWO SIGMA ADVISERS, LP 1.6% 874,100 +109% 0% $1,092,625
TWO SIGMA INVESTMENTS, LP 1.3% 706,061 +162% 0% $882,576
JACOBS LEVY EQUITY MANAGEMENT, INC 0.99% 524,350 +664% 0% $655,438
JANE STREET GROUP, LLC 0.94% 498,641 +31% 0% $623,301
Aldebaran Capital, LLC 0.9% 477,988 -5.2% 0.54% $597,485
MARSHALL WACE, LLP 0.87% 465,086 -24% 0% $581,358
GEODE CAPITAL MANAGEMENT, LLC 0.84% 446,140 +3.3% 0% $557,802
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.81% 428,853 +34% 0.01% $536,066
NORTHERN TRUST CORP 0.72% 382,088 +0.33% 0% $477,611
Walleye Capital LLC 0.63% 335,694 +21% 0% $419,618
BANK OF AMERICA CORP /DE/ 0.45% 240,138 +48% 0% $300,173
STATE STREET CORP 0.34% 183,178 +16% 0% $228,973
RBF Capital, LLC 0.3% 162,200 -34% 0.01% $202,750
Assenagon Asset Management S.A. 0.26% 140,468 +14% 0% $175,585
EVOKE WEALTH, LLC 0.25% 133,122 0% 0% $166,403

Institutional Holders of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 (PMVP) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 37,328,298 $46,659,218 -$174,773 $1.25 60
2025 Q3 37,492,718 $52,488,395 +$4,772,987 $1.40 63
2025 Q2 34,680,709 $36,758,763 -$2,911,770 $1.06 52
2025 Q1 37,320,031 $40,676,123 -$2,281,115 $1.09 54
2024 Q4 38,959,310 $58,833,270 -$767,790 $1.51 70
2024 Q3 39,023,873 $58,153,846 -$2,416,795 $1.49 73
2024 Q2 40,492,185 $65,594,864 -$3,771,661 $1.62 91
2024 Q1 42,725,320 $72,627,924 -$11,853,919 $1.70 96
2023 Q4 46,465,983 $144,025,863 -$52,160,467 $3.10 97
2023 Q3 54,236,025 $333,006,052 +$15,386,619 $6.14 103
2023 Q2 51,696,984 $323,689,509 +$3,281,155 $6.26 104
2023 Q1 51,513,177 $245,718,220 -$16,150,590 $4.77 111
2022 Q4 54,555,170 $474,625,571 -$38,255,414 $8.70 113
2022 Q3 58,187,852 $692,436,457 -$36,596,424 $11.90 116
2022 Q2 61,123,657 $870,921,498 +$53,476,878 $14.25 105
2022 Q1 55,249,345 $1,150,065,944 +$162,099,243 $20.82 98
2021 Q4 47,470,437 $1,096,597,184 +$15,190,740 $23.10 102
2021 Q3 43,990,444 $1,310,907,931 +$46,789,977 $29.80 91
2021 Q2 42,241,228 $1,442,956,792 +$80,038,413 $34.16 83
2021 Q1 39,915,363 $1,312,819,295 +$51,865,975 $32.89 81
2020 Q4 38,212,089 $2,335,342,669 +$185,049,476 $61.51 72
2020 Q3 31,212,908 $1,098,804,001 +$1,098,804,001 $35.50 51